Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application

By MarketWatch   |   1 year ago
Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application

Aldeyra Therapeutics' stock surged 11% as the FDA accepted its new drug application for dry eye disease treatment. The company's drug, reproxalap, shows promise in treating the condition.

Read More

Did you find this insightful?